head last night updat debat larg much agil
would beat consensu expect unfortun pronounc april weak china
food global small molecul pharma seemingli trade relat drove agil miss
expect cut revenu outlook pillar thesi remain intact howev
reduc price target
total core revenu growth y/i light sell side consensu high
end manag guidanc lsag clear driver miss core revenu declin
y/i cowen forecast y/i favor comparison acg growth bit
better forecast vs dgg core growth like
line consensu albeit light forecast
gross margin better expect oper spend dead-on
forecast howev oper margin still expect due
revenu shortfal still expand y/i disappoint perform
lsag oper margin declin y/i like function revenu
weak materi ep y/i light consensu
light forecast better expect non-oper item tax rate share count
ad vs forecast
core revenu growth guidanc reduc
cut midpoint appear larg function china sale
manag cut embed growth expect china hsd lsd
reduct growth translat specif believ agil
cut outlook china food growth outlook china small molecul
growth due larg implic gener program china
extens msd global biopharma growth expect manag re-affirmed
fy ep guidanc
recogn go hot button issu agil group
want stress dont believ reduct agil china growth outlook
function us-china trade disput china food ministri reorgan
headwind agil year gener drug purchas polici
also relat on-going us-china trade disput grew y/i china
observ suggest us agil china headwind transitori due
escal trade tension
agil still look well posit drive oper margin expans
hit prior ep target look ahead core revenu growth look
reason even current headwind persist still seem plausibl nasd
y/i tailwind either way feel good ep approxim continu
pleas see page report import disclosur
continu view agil posit competit perspect continu
believ compani post averag revenu earn growth
forese futur contrari peer agil still multipl avenu upsid outsid
core oper buybacks/m tax rate like near- long-term outlook rate
share outperform price target base dcf analysi
multipl group
ep growth continu approxim
low mid teen
agil acquir larger
organ growth oper margin
exceed
growth expect
possibl addit
lack growth render multipl high
growth lower expect china
expect margin expans fail
life scienc diagnost chemic analysi compani
compani current oper segment life scienc appli market lsag
diagnost genom dgg agil crosslab group acg
addit agil met intern china forecast april subsequ late-march/
early-april intern reduct seemingli demonstr near-term visibl
bad confid agil abil forecast china took hit manag
sound pretti bullish china ceo road mid-march
concern compani overli bullish set timelin food rebound
china prove well-found china issu arent trade-rel observ
ostens heighten concern manag might best visibl
chang trend addit note order april met agil reduc
bottom line agil still look well posit gener core revenu growth
expand margin gener solid cash flow reduc tax
rate use pristin balanc sheet support capit deploy howev seem
appropri take conserv stanc cut price target
expect headlin agil reduc outlook due china
note agil issu seemingli broader macroeconom trade
relat fact note europ us track line-to-ahead
expect context look like probabl best/safest place
larg cap tool mayb broader healthcar view
remain unaffect although scrub model base exposur
near term get redempt outlier seem prior
agil updat focu impact on-going small molecul food challeng
china may actual heighten concern cut outlook enough
broadli good remind compani well run
fundament long-term demand profil tool remain attract group valuat
doesnt allow mani bump road
compani report thomson eikon cowen compani
cowen vs consensu mm except core core gross y/i expans re-stat segment metric mm except growth growth growth statement mm except growth currenc expens expect though came expect sale due revenu miss margin better expectedpre-tax rate better expect net per count consensu growth revenu came forecast consensu growth y/i expect consensu rel model lsag drove major miss dgg also slightli miss expect full year guidanc also materi reduc entir within lsag lsag weak attribut china food weak global small molecul pharma weak within small molecul weak china gener market also pronounc expect overal china growth y/i quarter influenc food gener weak well expect consid favor comparison full year guidanc reduc accordingli outsid strong recur revenu growth mani bright spot gross margin came ahead expect everi segment gross margin perform ep forecast better expect non-oper expens tax rate share count collect ad ep vs forecast streetaccount consensu lsag revenu came forecast consensu revenu declin y/i well forecast y/i growth manag attribut weak two primari factor weak china food global small molecul weak includ poor china gener result due polici chemical/energi environmental/forens larg molecul biopharma grew regard pace manag note weak primarili occur late quarter march also note order trend improv april said guidanc assum weak china food persist weak global small molecul result poor revenu growth oper margin came forecast streetaccount consensu acg revenu came forecast though consensu growth y/i forecast solid acg quarter strong growth across servic consum manag note strong growth region includ mid-teen y/i core growth china acg continu grow hsd beyond oper margin came forecast streetaccount consensu dgg revenu came forecast consensu growth y/i forecast manag cite hsd growth patholog mid-teen growth nasd impli weaker perform genom though manag note relat genom product target enrich qc grew hsd manag note particular strength adjust oper margin came forecast though still expand y/i larg expect cowen
compani report cowen compani
mm except per share datajan net net core core fx arevenu acq core fx currenc contribut adjust segmentlif scienc appli group currenc contribut adjust crosslab group currenc contribut adjust genom group currenc contribut adjust currenc currenc pacif growth china hsd currenc currenc currenc compani averag capit mixreport currenc end marketpharma msd hsd lsd re-affirmed mid-singl digit flat slightli y/i total food biz chinareport cowen
compani report thomson eikon cowen compani
mm except per share datajan core core fx aorgan core fx aconst gener oper y/i expans re-stat basi pension cost incom opex see non-oper interest chang pension account move op incometo incom well keysight incomeearn tax rate net earn per re-affirmed expectationsjan gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit macroeconom deterior
current level challeng china disrupt due keysight spin eros market
share price due competit inabl deliv incremental/decrement margin
target value-destruct
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
